July 2026
Added to Dediabetes Jul 21, 2026RCTs
This study evaluated the effects of combined high-intensity interval training and progressive resistance training on overweight/obese adults, finding significant improvements in hepatic steatosis and fitness metrics.
Interventions
Resistance trainingTelehealth intervention
Outcomes
Change in body composition after 12 weeks of treatmentChange in physical fitness after 12 weeksHepatic Steatosis (Sensitivity Analysis)+3 more
Added to Dediabetes Jul 21, 2026RCTs
This study evaluated the effectiveness of tirzepatide in resolving metabolic dysfunction-associated steatohepatitis (MASH) without worsening fibrosis.
Outcomes
Fibrosis improvement without worsening of MASHResolution of Metabolic Dysfunction Associated Steatohepatitis (MASH)
Added to Dediabetes Jul 21, 2026RCTs
This study examined the effects of Empagliflozin on liver health in patients with Type 2 Diabetes Mellitus, finding significant improvements in liver fat and liver enzyme levels.
Interventions
Empagliflozin
Outcomes
ASTAlanine Aminotransferase (ALT)Reduction in liver fat grade from MRI assessments+2 more
Added to Dediabetes Jul 21, 2026RCTs
This study evaluated the efficacy and safety of dapagliflozin in participants with metabolic dysfunction-associated steatohepatitis (MASH), finding significant improvements in liver health outcomes.
Interventions
Dapagliflozin
Outcomes
Fibrosis improvement without worsening of MASHMean difference in non-alcoholic fatty liver disease activity score (NAS)Resolution of Metabolic Dysfunction Associated Steatohepatitis (MASH)
Added to Dediabetes Jul 21, 2026RCTs
This study analyzed health-related quality of life (HRQoL) in dietary interventions for type 2 diabetes, finding improvements in both low-carbohydrate high-fat (LCHF) and high-carbohydrate low-fat (HCLF) diets.
Interventions
Low-carbohydrate diet
Outcomes
Health-related quality of lifeTreatment adherence
Added to Dediabetes Jul 21, 2026RCTs
The study investigated the effects of adding Empagliflozin to standard treatment in patients with Type 2 Diabetes, finding significant reductions in hepatic fat mass and BMI.
Interventions
Empagliflozin
Outcomes
Alanine Aminotransferase (ALT)BMIFIB-4 index+3 more
Added to Dediabetes Jul 21, 2026RCTs
This study compared the effects of liraglutide and lifestyle counseling on metabolic outcomes in obese individuals with prediabetes or early type 2 diabetes, finding comparable improvements in key metrics.
Interventions
Behavioral counselingLiraglutide
Outcomes
BMIReduction in MASLD extent after weight lossReduction of IL-1β levels after weight loss+1 more
Added to Dediabetes Jul 21, 2026RCTs
This study investigated the impact of various interventions on metabolic health in individuals with type 2 diabetes, finding significant improvements in body weight, insulin sensitivity, triglycerides, and HbA1c levels.
Interventions
Intermittent Fasting (IF)Lifestyle intervention for prediabetesResistance training
Outcomes
Body weightHbA1cInsulin sensitivity+1 more
Added to Dediabetes Jul 21, 2026RCTs
The study evaluated the effects of Tirzepatide combined with either Low-Energy Ketogenic Therapy or Low-Calorie Diet on hepatic steatosis in patients with MASLD, finding significant improvements in liver parameters.
Outcomes
BMIControlled attenuation parameterHbA1c+1 more
Added to Dediabetes Jul 21, 2026RCTs
This study evaluated the effects of ertugliflozin on liver function in patients with nonalcoholic fatty liver disease and type 2 diabetes, finding significant improvements in liver-related biomarkers.
Interventions
Ertugliflozin
Outcomes
ASTAlanine Aminotransferase (ALT)Body weight+10 more
